3rd Dry AMD Therapeutics Summit
Evvnt Promotion / evvnt
Archivo
30.11.2022 - 02.12.2022 Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 07:50 - 12:00
Temas de la conferencia
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Información e inscripción:
https://go.evvnt.com/1279770-2?pid=4832
Ms. Stephanie Nketia
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
